Search This Blog

Thursday, December 30, 2021

Madrigal Updates on Timeline for Phase 3 Topline Results from NASH Trial

 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease, presumed NASH.

Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “Although the blinded study data were delivered to the vendor conducting the statistical analyses on time, unexpected staffing issues at the vendor delayed their analyses of the initial MRI-PDFF and lipid data planned for release by year end. We now expect to announce topline 52-week results from the study in January 2022.”

https://finance.yahoo.com/news/madrigal-provides-timeline-topline-results-130000860.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.